SunOpta reports record revenues despite writing down Mascoma investment
For the quarter ended June 29, 2013 the Company incurred a loss from continuing operations of $15.0 million or $0.23 per diluted common share, compared to earnings from continuing operations of $7.3 million or $0.11 per diluted common share for the second quarter of 2012. Included in the results for the second quarter is a non-cash charge of approximately $21.5 million after tax, or $0.32 per diluted common share, representing a 64% write-down of the carrying value of the Company's non-core investment in Mascoma Corporation. In assessing the fair value the Company considered a number of factors including the values of comparable public companies in the renewable energy space, which have experienced declines in value that no longer appear to be of a temporary nature. The Company's investment in Mascoma was established in the third quarter of 2010 following the sale of SunOpta BioProcess Inc. in return for a minority equity stake in Mascoma. At that time, a non-cash gain on sale was recognized and adjusted earnings were reported to remove the effect of the gain. Excluding the Mascoma impairment charge, adjusted earnings from continuing operations in the second quarter of 2013 were $6.5 million or $0.10 per diluted common share. In addition, earnings for the second quarter include the impact of approximately $1.7 million in pre-tax severance, acquisition and start-up costs, or approximately $1.0 million after-tax and minority interest.
LATEST NEW HAMPSHIRE ANGLE
Heroin bust suspect also a registered sex offender, child in home at time of drug arrest was grandchild
Derry fire displaces five
What's open / what's closed on Thanksgiving